CytomX Therapeutics, Inc. (CTMX)
Largest Insider Buys in Sector
CTMX Stock Price History Chart
CTMX Stock Performance
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and …
Insider Activity of CytomX Therapeutics, Inc.
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $134,664 worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $459,277 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
List of Insider Buy and Sell Transactions, CytomX Therapeutics, Inc.
| 2024-08-20 | Sale | CEO | 13,898 0.0176% | $1.23 | $17,082 | -7.26% | ||
| 2024-08-20 | Sale | SVP, Chief Scientific Officer | 4,181 0.0053% | $1.23 | $5,139 | -7.26% | ||
| 2024-08-20 | Sale | General Counsel | 4,181 0.0053% | $1.23 | $5,139 | -7.26% | ||
| 2024-08-20 | Sale | Chief Business Officer | 4,181 0.0053% | $1.23 | $5,139 | -7.26% | ||
| 2024-08-20 | Sale | Chief Financial Officer | 1,984 0.0025% | $1.23 | $2,439 | -7.26% | ||
| 2024-03-19 | Sale | CEO | 20,223 0.0286% | $2.09 | $42,175 | -41.74% | ||
| 2024-03-19 | Sale | SVP, Chief Scientific Officer | 12,795 0.0181% | $2.09 | $26,684 | -41.74% | ||
| 2024-03-19 | Sale | General Counsel | 5,268 0.0074% | $2.09 | $10,986 | -41.74% | ||
| 2024-03-19 | Sale | Chief Business Officer | 6,562 0.0093% | $2.09 | $13,685 | -41.74% | ||
| 2024-03-19 | Sale | SVP, Finance and Accounting | 2,971 0.0042% | $2.09 | $6,196 | -41.74% | ||
| 2023-12-20 | Sale | CEO | 13,551 0.0208% | $1.38 | $18,710 | +11.28% | ||
| 2023-12-20 | Sale | SVP, Chief Scientific Officer | 4,077 0.0063% | $1.38 | $5,628 | +11.28% | ||
| 2023-12-20 | Sale | General Counsel | 4,077 0.0063% | $1.38 | $5,629 | +11.28% | ||
| 2023-12-20 | Sale | Chief Business Officer | 4,077 0.0063% | $1.38 | $5,628 | +11.28% | ||
| 2023-12-20 | Sale | SVP, Finance and Accounting | 1,990 0.0031% | $1.38 | $2,747 | +11.28% | ||
| 2023-09-22 | Sale | CEO | 14,601 0.0222% | $1.30 | $18,987 | +14.06% | ||
| 2023-09-22 | Sale | SVP, Chief Scientific Officer | 4,119 0.0063% | $1.30 | $5,356 | +14.06% | ||
| 2023-09-22 | Sale | General Counsel | 5,486 0.0083% | $1.30 | $7,135 | +14.06% | ||
| 2023-09-22 | Sale | Chief Business Officer | 4,119 0.0063% | $1.30 | $5,356 | +14.06% | ||
| 2023-03-29 | director | 5,000 0.0076% | $1.55 | $7,750 | +0.33% |
Insider Historical Profitability
| ROWLAND LLOYD A | General Counsel | 130797 0.1671% | $1.09 | 1 | 6 | <0.0001% |
| Flynn James E | 10 percent owner | 671024 0.8574% | $1.09 | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.3471% | $1.09 | 1 | 8 | <0.0001% |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0178% | $1.09 | 1 | 1 | <0.0001% |
| Jones Elaine V | director | 5142 0.0066% | $1.09 | 1 | 0 | +0.33% |
Institutional Investor Ownership
| Bvf Inc Il | $14.38M | 8.47 | 6.6M | 0% | +$0 | 0.11 | |
| Tang Capital Management, LLC | $14.06M | 8.28 | 6.45M | -1.53% | -$218,000.00 | 0.05 | |
| The Vanguard Group | $10.59M | 6.23 | 4.86M | -0.93% | -$99,340.43 | <0.0001 | |
| OrbiMed | $7.73M | 4.55 | 3.54M | New | +$7.73M | 0.06 | |
| Acadian Asset Management | $5.86M | 3.45 | 2.69M | +1.69% | +$97,265.27 | 0.02 |